BDNF / TrkB enhancement to treat neurodegenerative diseases
Over 30 years ago a major advance was made by identifying a critical nerve growth factor. It is called brain-derived neurotrophic factor (BDNF), and it offers the possibility of major new treatments for many brain disorders. It acts by binding to TrkB receptors to increase central nervous system growth, resiliency, and connections between nerves.
Enhancing the BDNF / TrkB system has been shown to have multiple benefits for brain health via increased neuroplasticity. Such enhancements may potentially treat and/or prevent neurodegenerative disorders such as Alzheimer’s Disease.
ZYL-314 is a novel patented drug specifically designed to enhance BDNF / TrkB activation. Preclinical studies to date strongly support its effectiveness for a wide range of beneficial neuroplasticity changes.
ZYL-314 is a platform for several drugs in development based upon the exciting neuroplasticity changes. These drugs have the potential to address multiple unmet needs in neurodegenerative and neuropsychiatric areas.
